glp 1 drugs and cancer Glucagon-like peptide-1 medicines GLP-1 drugs may be linked
Description
Abdominal fat particularly raises the risk of insulin resistance
Evidence based on recent studies Initially, cases of intestinal obstruction associated with GLP-1 RAs were reported by the European Medicines Agency (EMA) in 2013 [9], and this safety signal is currently being monitored by the United States (US) FDA
The current report discusses the mechanism of action, classification, pharmacokinetic and pharmacodynamic properties of various GLP-1 RAs
.png?w=1536&max-h=2752&fit=crop&auto=format)
More than 50 brand names from 40+ manufacturers expected by end of 2026
J Appl Physiol (1985) (2017) 123(1):718
